NCT03497195

Brief Summary

To achieve TB control, innovative case finding interventions are needed that will reach the broader affected population including those that do not access the health facilities. Systematic community case finding with highly sensitive screening and diagnostic tools are needed. At the facility level, the index of suspicion for TB by health care workers needs to be raised to ensure that all those that need TB screening are appropriately screened.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18,194

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2017

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 6, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 13, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

September 25, 2019

Status Verified

September 1, 2019

Enrollment Period

1.5 years

First QC Date

April 6, 2018

Last Update Submit

September 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • increase TB case detection

    comparison of two diagnostic tools (Chest Xray with CAD versus CRP) and Xpert Ultra for active community based TB case detection

    6 months

Study Arms (2)

Community level screening; Arm 1

ACTIVE COMPARATOR

use of chest X-ray plus Xpert Ultra for community level TB screening

Diagnostic Test: Screening at community level

Community level screening: Arm 2

ACTIVE COMPARATOR

use of C-reactive Protein and Xpert Ultra for community level TB screening

Diagnostic Test: Screening at community level

Interventions

comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening

Community level screening: Arm 2Community level screening; Arm 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Program Implementation:
  • Any adult or child with TB symptoms (weight loss, chest pain, shortness of breath, fever, cough, hemoptysis, night sweats)
  • Ability to produce sputum
  • Verbal consent of parent or guardian if \< 18 years old
  • Operations Research:
  • Adults (18 years and older)
  • TB symptoms (weight loss, chest pain, shortness of breath, fever, cough, hemoptysis, night sweats)
  • Ability to provide a sputum sample
  • Willing to provide written informed consent
  • Willing to undergo full clinical evaluation
  • Willing to undergo a CXR

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Infectious Disease Research in Zambia (CIDRZ)

Lusaka, 10102, Zambia

Location

Related Publications (1)

  • Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD009593. doi: 10.1002/14651858.CD009593.pub5.

MeSH Terms

Conditions

Tuberculosis

Condition Hierarchy (Ancestors)

Mycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Study Officials

  • Monde Muyoyeta, MD,PhD

    Center for Infectious Disease Research in Zambia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Primary Investigator

Study Record Dates

First Submitted

April 6, 2018

First Posted

April 13, 2018

Study Start

July 1, 2017

Primary Completion

December 31, 2018

Study Completion

December 31, 2018

Last Updated

September 25, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations